.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Prof. Hubert Schrezenmeier

Weitere Beteiligungen

22.09.2022
13:50 – 14:00 6 Min. 4 Min.
Abstractvortrag
VS-13-3
Long-term Follow up (> 1 year) of Plasma Donors and Patients treated with COVID-19 Convalescent Plasma within the CAPSID trial
19. COVID-19, 9. Hämotherapie
22.09.2022
14:00 – 14:10 6 Min. 4 Min.
Abstractvortrag
VS-13-4
A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new pathogen: Experience from collection of very high-titer plasma from superimmunized individuals
1. Blutspende und Donormanagement, 19. COVID-19
22.09.2022
16:00 – 16:10 6 Min. 4 Min.
Abstractvortrag
VS-16-2
Higher risk for chronic graft-versus-host disease (GvHD) in HLA-G mismatched transplants following allogeneic hematopoietic stem cell transplantation (allo-HSCT)
8. Immungenetik: HLA und Transplantationen
22.09.2022
17:00 – 17:05 3 Min. 2 Min.
Poster
PS-5-9
Detection of SARS-CoV-2 Spike-Protein-Specific Antibodies after Vaccination via Nasal and Buccal Swabs: Prospects for Mass Scale Immunity-Screening in Large Populations
19. COVID-19
22.09.2022
17:25 – 17:30 3 Min. 2 Min.
Poster
PS-4-14
Ex-vivo expansion of autologous bone marrow-derived mesenchymal stromal cells for treatment of bone defects: Impact of donors characteristics and quality of starting material of efficacy of expansion
12. Zelltherapie und Gentherapie, 18. Zukunftsgebiete der Transfusionsmedizin
22.09.2022
17:40 – 17:45 3 Min. 2 Min.
Poster
PS-5-17
BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages
18. Zukunftsgebiete der Transfusionsmedizin, 19. COVID-19
23.09.2022
09:30 – 09:40 6 Min. 4 Min.
Abstractvortrag
VS-19-5
Phase I clinical trial on hematopoietic stem cell recipients transfused with FFP from donors with highly potent anti-CMV antibodies
13. Neue Blutprodukte – Neue Anwendungen, 18. Zukunftsgebiete der Transfusionsmedizin
23.09.2022
09:50 – 10:00 6 Min. 4 Min.
Abstractvortrag
VS-21-9
Upregulation of check-point ligand PD-L1 in patients with PNH explained by proximal complement activation
7. Immunhämatologie und Immunologische Grundlagen, 9. Hämotherapie